Known targets — ChEMBL curated mechanism
MMP1MMP13MMP7MMP8rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Doxycycline Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP7 known ✓ | P09237 | 1/20 | 0.69 |
| ▸ | MMP8 known ✓ | P22894 | 1/20 | 0.69 |
| ▸ | MMP13 known ✓ | P45452 | 1/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 10/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.69 |
| ▸ | L3MBTL1 | Q9Y468 | 7/20 | 0.69 |
| ▸ | USP2 | O75604 | 6/20 | 0.69 |
| ▸ | MMP2 | P08253 | 1/20 | 0.69 |
| ▸ | MMP3 | P08254 | 1/20 | 0.69 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.69 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.68 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.68 |
| ▸ | TSHR | P16473 | 1/20 | 0.68 |
| ▸ | RECQL | P46063 | 7/20 | 0.67 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.67 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.67 |
| ▸ | HPGD | P15428 | 7/20 | 0.49 |
| ▸ | MEN1 | O00255 | 6/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Doxycycline Anhydrous SCHEMBL497165 | 1.00 | TDP1 (0.69) | TDP1KDM4EL3MBTL1USP2MMP2 | |
| Doxycycline Anhydrous SCHEMBL17747966 | 1.00 | TDP1 (0.69) | TDP1KDM4EL3MBTL1USP2MMP2 | |
| Doxycycline Anhydrous SCHEMBL497163 | 1.00 | TDP1 (0.69) | TDP1KDM4EL3MBTL1USP2MMP2 | |
| Doxycycline Anhydrous SCHEMBL8709949 | 1.00 | TDP1 (0.69) | TDP1KDM4EL3MBTL1USP2MMP2 | |
| Doxycycline Anhydrous SCHEMBL29151798 | 1.00 | TDP1 (0.69) | TDP1KDM4EL3MBTL1USP2MMP2 | |
| Doxycycline Anhydrous SCHEMBL8709954 | 0.99 | TDP1 (0.70) | TDP1KDM4EL3MBTL1USP2MMP2 | |
| Doxycycline Anhydrous SCHEMBL11417262 | 0.99 | MMP2 (0.70) | TDP1KDM4EL3MBTL1USP2MMP2 | |
| Doxycycline Anhydrous SCHEMBL8683380 | 0.99 | MMP2 (0.70) | TDP1KDM4EL3MBTL1USP2MMP2 | |
| Doxycycline Anhydrous SCHEMBL41883 | 0.99 | MMP2 (0.70) | TDP1KDM4EL3MBTL1USP2MMP2 | |
| Doxycycline Anhydrous SCHEMBL40834 | 0.99 | TDP1 (0.70) | TDP1KDM4EL3MBTL1USP2MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 143 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018191529-A1 | DENTAL VARNISHES THAT RELEASE SPECIFICALLY TARGETED ANTIMICROBIAL PEPTIDES AND/OR FLUORIDE | C3 JIAN, LLC (US) | 2018-10-18 | — | — | WO | claimed |
| CN-103655593-B | Composite medicine preparation for prevention and treatment of bacterium and virus polyinfection diseases of livestock as well as preparation method and application thereof | TIANJIN ZHONGSHENG GROUP | 2015-05-13 | — | — | CN | claimed |
| US-20140206635-A1 | METAL-SALEN COMPLEX COMPOUND, LOCAL ANESTHETIC AND ANTINEOPLASTIC DRUG | IHI CORPORATION (JP) | 2014-07-24 | — | — | US | claimed |
| EP-2738158-A1 | METAL SALEN COMPLEX COMPOUND, LOCAL ANESTHETIC, AND ANTI-MALIGNANT TUMOR AGENT | IHI Corporation (JP) | 2014-06-04 | — | — | EP | claimed |
| CN-103655593-A | Composite medicine preparation for prevention and treatment of bacterium and virus polyinfection diseases of livestock as well as preparation method and application thereof | TIANJIN ZHONGSHENG GROUP | 2014-03-26 | — | — | CN | claimed |
| US-20140046021-A1 | SELF-MAGNETIC METAL-SALEN COMPLEX COMPOUND | IHI CORPORATION (JP) | 2014-02-13 | — | — | US | claimed |
| EP-2682384-A1 | AUTO-MAGNETIC METAL SALEN COMPLEX COMPOUND | IHI Corporation (JP) | 2014-01-08 | — | — | EP | claimed |
| CN-102133213-B | Veterinary compound florfenicol injection and preparation method thereof | HUBEI WUDANG ANIMAL PHARMACEUTICAL CO LTD | 2013-04-10 | — | — | CN | claimed |
| US-8036738-B2 | Iontophoretic transdermal drug delivery system based on conductive polyaniline membrane | NEW JERSEY INSTITUTE OF TECHNOLOGY (US) | 2011-10-11 | — | — | US | claimed |
| CN-102133213-A | Veterinary compound florfenicol injection and preparation method thereof | HUBEI WUDANG ANIMAL PHARMACEUTICAL CO LTD | 2011-07-27 | — | — | CN | claimed |
| US-20070232985-A1 | Iontophoretic transdermal drug delivery system based on conductive polyaniline membrane | NEW JERSEY INSTITUTE OF TECHNOLOGY | 2007-10-04 | — | — | US | claimed |
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | ERESINA LLC (US) | 2026-04-16 | — | — | US | disclosed |
| US-20260027215-A1 | COMPOSITIONS FOR TRANSPORT OF THERAPEUTIC CARGOS USING BINDERS TARGETING CA-IV | RECEPTIVE BIO INC (US) | 2026-01-29 | — | — | US | disclosed |
| EP-4393512-B1 | COMPOSITION FOR PHARMACEUTICAL TABLET, PHARMACEUTICAL TABLET USING THE SAME, AND MANUFACTURING METHOD THEREOF | MITSUBISHI CHEM CORP (JP) | 2025-10-01 | — | — | EP | disclosed |
| EP-4062144-B1 | DEVICE FOR EXTRACTING A MOLECULE OF INTEREST FROM A SAMPLE MATRIX | JP SCIENT LIMITED (CA) | 2025-08-06 | — | — | EP | disclosed |
| WO-2001000164-A1 | COSMETIC COMPOSITIONS CONTAINING VITAMIN B3 | THE PROCTER & GAMBLE COMPANY (US) | 2001-01-04 | — | — | WO | disclosed |
| EP-0952171-A2 | Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof | Poly-Med Inc. (US) | 1999-10-27 | — | — | EP | disclosed |
| US-5904929-A | Acylated cyclodextrin-containing pharmaceutical composition | JANSSEN PHARMACEUTICA, N.V. (BE) | 1999-05-18 | — | — | US | disclosed |
| US-5800838-A | Composition that inhibits or destroys at least one unicellular living organism containing fluorine F- and Lithium li+ | ATLANTIC PHARMACEUTICAL PRODUCTS LIMITED (FR) | 1998-09-01 | — | — | US | disclosed |
| US-5662941-A | ANTIBIOTICS | BOURBON PIERRE (FR) | 1997-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140206635-A1 | METAL-SALEN COMPLEX COMPOUND, LOCAL ANESTHETIC AND ANTINEOPLASTIC DRUG | NCLN, KCNN2, NCSTN | MMP7 1358/4885MMP8 186/4885MMP13 766/4885 |
| US-20140046021-A1 | SELF-MAGNETIC METAL-SALEN COMPLEX COMPOUND | SSBP1, KCNN1, IMMT | MMP7 890/4885MMP8 3301/4885MMP13 2178/4885 |
| US-20260027215-A1 | COMPOSITIONS FOR TRANSPORT OF THERAPEUTIC CARGOS USING BINDERS TARGETING CA-IV | CA4, FLT4, CAMK4 | MMP7 531/4885MMP8 476/4885MMP13 137/4885 |
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | COL2A1, COLGALT1, PLOD3 | MMP7 1265/4885MMP8 94/4885MMP13 122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.